Ketterer K - Search Results

1

Y-chromosome loss is frequent in male renal tumors.

Büscheck F, Fraune C, Garmestani S, Simon R, Kluth M, Hube-Magg C, Ketterer K, Eichelberg C, Höflmayer D, Jacobsen F, Wittmer C, Wilczak W, Sauter G, Fisch M, Eichenauer T, Rink M. Büscheck F, et al. Among authors: ketterer k. Ann Transl Med. 2021 Feb;9(3):209. doi: 10.21037/atm-20-3061. Ann Transl Med. 2021. PMID: 33708836 Free PMC article.

2

Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes.

Büscheck F, Fraune C, Simon R, Kluth M, Hube-Magg C, Möller-Koop C, Sarper I, Ketterer K, Henke T, Eichelberg C, Dahlem R, Wilczak W, Sauter G, Fisch M, Eichenauer T, Rink M. Büscheck F, et al. Among authors: ketterer k. Oncotarget. 2020 Jan 21;11(3):237-249. doi: 10.18632/oncotarget.27428. eCollection 2020 Jan 21. Oncotarget. 2020. PMID: 32076485 Free PMC article.

3

Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function.

Bachmann J, Ketterer K, Marsch C, Fechtner K, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME. Bachmann J, et al. Among authors: ketterer k. BMC Cancer. 2009 Jul 28;9:255. doi: 10.1186/1471-2407-9-255. BMC Cancer. 2009. PMID: 19635171 Free PMC article.

4

Liver macrophages contribute to pancreatic cancer-related cachexia.

Martignoni ME, Dimitriu C, Bachmann J, Krakowski-Rosen H, Ketterer K, Kinscherf R, Friess H. Martignoni ME, et al. Among authors: ketterer k. Oncol Rep. 2009 Feb;21(2):363-9. Oncol Rep. 2009. PMID: 19148509

5

Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway.

Ketterer K, Kong B, Frank D, Giese NA, Bauer A, Hoheisel J, Korc M, Kleeff J, Michalski CW, Friess H. Ketterer K, et al. Cancer Lett. 2009 May 8;277(1):72-81. doi: 10.1016/j.canlet.2008.11.028. Epub 2008 Dec 31. Cancer Lett. 2009. PMID: 19118941

6

Abnormal crosstalk between pancreatic acini and macrophages during the clearance of apoptotic cells in chronic pancreatitis.

Bartel M, Hänsch GM, Giese T, Penzel R, Ceyhan G, Ketterer K, von Knebel-Döberitz M, Friess HM, Giese NA. Bartel M, et al. Among authors: ketterer k. J Pathol. 2008 Jun;215(2):195-203. doi: 10.1002/path.2348. J Pathol. 2008. PMID: 18421760

7

FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth.

Kayed H, Kleeff J, Kolb A, Ketterer K, Keleg S, Felix K, Giese T, Penzel R, Zentgraf H, Büchler MW, Korc M, Friess H. Kayed H, et al. Among authors: ketterer k. Int J Cancer. 2006 Jan 1;118(1):43-54. doi: 10.1002/ijc.21257. Int J Cancer. 2006. PMID: 16003754 Free article.

8

Tumor induced local fibrogenic effect by hepatic metastasis of insulinoma.

Longerich T, Ketterer K, Helmke BM, Friess H, Schirmacher P. Longerich T, et al. Among authors: ketterer k. Virchows Arch. 2005 Jun;446(6):680-1. doi: 10.1007/s00428-005-1267-6. Epub 2005 May 19. Virchows Arch. 2005. PMID: 15902484 No abstract available.

9

Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis.

Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA, Friess H. Erkan M, et al. Among authors: ketterer k. Oncogene. 2005 Jun 23;24(27):4421-32. doi: 10.1038/sj.onc.1208642. Oncogene. 2005. PMID: 15856026

10

Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer.

Arnold NB, Ketterer K, Kleeff J, Friess H, Büchler MW, Korc M. Arnold NB, et al. Among authors: ketterer k. Cancer Res. 2004 May 15;64(10):3599-606. doi: 10.1158/0008-5472.CAN-03-2999. Cancer Res. 2004. PMID: 15150118

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page